Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24626075 | 1.00 | DNM1 (0.47) | DNM1GAAFAAHKDM5AKDM4C | |
| SCHEMBL24625970 | 0.93 | DNM1 (0.46) | DNM1GAAFAAHKDM5AKDM4C | |
| SCHEMBL24626084 | 0.93 | DNM1 (0.46) | DNM1GAAFAAHKDM5AKDM4C | |
| SCHEMBL24626480 | 0.86 | GAA (0.51) | DNM1GAAFAAHCASP2PAOX | |
| SCHEMBL24626074 | 0.86 | GAA (0.51) | DNM1GAAFAAHCASP2PAOX | |
| SCHEMBL24626478 | 0.84 | DNM1 (0.61) | DNM1GAAFAAHCASP2ICMT | |
| SCHEMBL24626294 | 0.84 | DNM1 (0.61) | DNM1GAAFAAHCASP2ICMT | |
| SCHEMBL24626078 | 0.83 | DNM1 (0.38) | DNM1GAAFAAHKDM5AKDM4C | |
| SCHEMBL24626063 | 0.83 | DNM1 (0.38) | DNM1GAAFAAHKDM5AKDM4C | |
| SCHEMBL16479251 | 0.82 | DNM1 (0.53) | DNM1FAAHKDM5AKDM4CCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220065-A1 | ADDITIVE FOR ELECTROPLATING SOLUTIONS, ELECTROPLATING SOLUTION, ELECTROPLATING METHOD AND NOVEL COMPOUND | ADEKA CORPORATION (JP) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220065-A1 | ADDITIVE FOR ELECTROPLATING SOLUTIONS, ELECTROPLATING SOLUTION, ELECTROPLATING METHOD AND NOVEL COMPOUND | SLC26A3, CLCN2, AP1M1 | DNM1 1003/4885GAA 4389/4885FAAH 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.